Key statistics
On Thursday, Neurocrine Biosciences Inc (N1BI34:SAO) closed at 33.02, 40.75% above the 52 week low of 23.46 set on Oct 26, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 33.02 |
---|---|
High | 33.02 |
Low | 33.02 |
Bid | 30.55 |
Offer | 35.79 |
Previous close | 32.81 |
Average volume | 1.04k |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Sep 19 2024 11:00 BST.
More ▼
Press releases
- Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit
- Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia
- Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference
- Neurocrine Biosciences to Participate at Investor Conferences in September
- Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia
- Neurocrine Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference
- Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance
- Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing
- Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results
- Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH
More ▼